403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
LNAI Stock Soars Pre-Market After Immune Cell Therapy Gains Licensee Interest
(MENAFN- AsiaNet News)
Shares of Lunai Bioworks (LNAI) jumped 18% in the pre-market session on Tuesday after the company announced that it has secured its first letter of intent (LOI) to license its next-generation immune cell therapy.
The cell therapy, Dendritic Cell Combination Therapy (DCCT), achieved complete regression of both primary and metastatic pancreatic tumors with no recurrence in humanized preclinical models.
"We are seeing accelerating validation from both researchers and industry partners," said CEO David Weinstein. He added that the early licensing activity reflects growing confidence in this platform's potential to unlock scalable treatments.
Get updates to this developing story directly on Stocktwits.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment